计算溶液所需的质量、体积或浓度。
提供 ≥98% 纯度,适用于对基线干扰要求严格的色谱和分析工作流程。
2-8°C储存,干燥。低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 2 篇同行评审文献引用。
Enrofloxacin monohydrochloride (BAY Vp 2674 monohydrochloride) is an effective antibiotic with an MIC 90 of 0.312 μg/mL for Mycoplasma bovis . Enrofloxacin monohydrochloride shows inhibitory activity against vaccinia virus (VV).
In Vitro
Mycoplasma bovis is a worldwide pathogen, causative agent of pneumonia, mastitis, arthritis, and a variety of other symptoms in cattle. The antibiotic susceptibility profiles of the Hungarian strains are consistent within the tested group of fluoroquinolones. Three isolates (MYC44, MYC45 and MYC46) have high MIC values (≥10 μg/mL) to Enrofloxacin, while the rest of the strains are inhibited by Enrofloxacin with MICs ≤0.312 or 0.625 μg/mL. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Mice (n=80) undergo transient middle cerebral artery occlusion (MCAo) with reperfusion after 60 minutes. After MCAo, animals are randomly assigned to receive either a daily preventive medication (n=26, Enrofloxacin) starting at the day of MCAo or a therapeutic medication (n=25; Enrofloxacin) after diagnosis of lung infection. Standard treatment started immediately after the appearance of clinical signs (general health score>6) usually between day 4 and 6 after stroke. Both, preventive and standard antibiotic treatment using Enrofloxacin improve survival in a similar way compared with placebo treatment. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal administration
Mice 11- to 14-week-old C57Bl6/J male mice are used. Enrofloxacin (2.5% oral solution) is dispensed in saline (2 mg/mL), antibiotic-treated animals receive a daily orally dispensed dose of 10 mg/kg body weight via feeding needle every 12 hours over a period of 7 days, while placebo animals receive the same amount of saline via feeding needle. Animals of preventive antibiotic group obtained Enrofloxacin after waking from reperfusion anesthesia (ca. 1 hour after operation). Therapeutic antibiotic treatment is given immediately after appearance of clinical signs (general health score>5) and confirmation of lung infection by MRI (signal rate≥5%). The group allocation is randomized . aladdin has not independently confirmed the accuracy of these methods. They are for reference only.
Form:Solid
IC50& Target:Quinolone
分类树(Taxonomy Tree)
| 界(kingdom) | 有机化合物 |
|---|---|
| 超类(Superclass) | 有机杂环化合物 |
| 类(Class) | 喹啉及其衍生物 |
| 亚类(Subclass) | 喹啉羧酸 |
| 中间层级节点(Intermediate Tree Nodes) | 暂无 |
| 直接上位类(Direct Parent) | 喹啉羧酸 |
| 其他上位类(Alternative Parents) | 氟喹诺酮类药物 N-芳基哌嗪 卤代喹啉 氢化喹诺酮类药物 氨基喹啉及其衍生物 氢化喹啉 吡啶羧酸 二烷基芳胺 N-烷基哌嗪 芳基氟化物 苯类化合物 杂芳族化合物 乙烯基酰胺 三烷基胺 氨基酸 氮杂环化合物 羧酸 碳氢化合物衍生物 盐酸盐 有机氧化物 有机氟化物 有机氧化合物 |
| 分子骨架(Molecular Framework) | 芳香族杂多环化合物 |
| 取代基(Substituents) | 1,4-二氮杂环丁烷 - 氨基酸 - 氨基酸 - 氨基酸或其衍生物 - 氨基吡啶 - 芳香族杂多环化合物 - 芳基氟化物 - 芳基卤化物 - 氮杂环 - 苯基化合物 - 羧酰胺基 - 羧酸衍生物 - 二烷基芳基胺 - 二氢喹啉 - 二氢喹啉酮 - 氟喹啉酮 - 卤喹啉 - 杂芳香族化合物 - 烃衍生物 - 氟氯烃 - N-烷基哌嗪 - N-芳基哌嗪 - 有机硝基化合物 - 有机氧化物 - 有机氧化合物 - 有机氟化物 - 有机卤化物 - 有机氮化合物 - 有机氧化合物 - 哌嗪 - 吡啶 - 吡啶羧酸 - 吡啶羧酸或其衍生物 - 喹啉-3-羧酸 - 三元脂肪胺 - 三级脂肪族/芳香族胺 - 三芳基胺 - 乙烯酰胺 |
| 描述(Description) | 该化合物属于喹啉羧酸类有机化合物。此类化合物以喹啉为母体,其喹啉环系在单个或多个位置被羧基取代。 |
| 外部描述符(External Descriptors) | 暂无 |
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
| 分析证书 | E649718 | |
| 分析证书 | E649718 | |
| 分析证书 | E649718 | |
| 分析证书 | E649718 | |
| 分析证书 | E649718 | |
| 分析证书 | E649718 | |
| 分析证书 | E649718 | |
| 分析证书 | E649718 | |
| 分析证书 | E649718 | |
| 分析证书 | E649718 | |
| 分析证书 | E649718 | |
| 分析证书 | E649718 | |
| 分析证书 | E649718 |